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Abstract: Saponin fractions of Quillaja saponaria Molina (QS) have cytotoxic activity against 
cancer cells in vitro, but are too toxic to be useful in the clinic. The toxic effect was abolished by 
converting QS fractions into stable nanoparticles through the binding of QS to cholesterol. Two 
fractions of QS were selected for particle formation, one with an acyl-chain (ASAP) was used to 
form killing and growth-inhibiting (KGI) particles, and the other without the acyl-chain (DSAP) 
was used to formulate blocking and balancing effect (BBE) particles. KGI showed significant 
growth inhibiting and cancer cell-killing activities in nine of 10 cell lines while BBE showed 
that on one cell line. The monoblastoid lymphoma cell line U937 was selected for analyzing the 
mode of action. Low concentrations of KGI (0.5 and 2 µg/mL) induced irreversible exit from 
the cell cycle, differentiation measured by cytokine production, and eventually programmed cell 
death (apoptosis). Compared to normal human monocytes, the U937 cells were 30-fold more 
sensitive to KGI. The nontoxic BBE blocked the cell killing effect of KGI in a concentration-
dependent manner. In conclusion, the formulation of QS into nanoparticles has the potential of 
becoming a new class of anticancer agents.
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Introduction
Pharmacological treatment of cancer makes continuous progress, but with some few 
exceptions, the new “targeted” drugs only provide marginal benefit as single drugs or in 
combination with established drugs.1 Thus, there is an urgent need to identify and develop 
new anticancer drugs acting by new principles evading the drawbacks of currently available 
drugs. Saponins belong to a group of naturally derived compounds, which have demon-
strated substantial cytotoxic activity through different mechanisms in vitro.2–4 Astragalus 
saponin (AST) inhibits cell proliferation through accumulation in S phase and G2/M arrest, 
with concomitant suppression of p21 expression and inhibition of cyclin-dependent kinase 
activity. Furthermore, it promotes apoptosis in HT-29 cells through caspase 3 activation 
and poly(ADP-ribose) polymerase cleavage.5 Ginseng saponin induces apoptosis via 
p53 and p21 activation and down regulates cell cycle-related proteins.6 Saponin extracts 
from the Quillaja saponaria Molina (QS) tree exhibit diverse biological activities such 
as hemolytic, anti-inflammatory, immune-stimulatory, antiviral, and cytotoxic activities.7 
QS is well studied and characterized, and has been fractionated into 21 or more fractions 
by reverse phase chromatography.8,9 The more hydrophobic fractions have an acyl-chain, 
ie, acyl-saponin (ASAP) corresponding to QS 218 or QHC,10 rendering them highly cell 
lytic while the less hydrophobic fractions are lacking the acyl-chain, ie, desacyl-saponin 
(DSAP) corresponding to QS 78 or QHA,10 having a low cell lytic effect.International Journal of Nanomedicine 2010:5 52
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The crude and ASAP fractions of QS cause side effects 
because of their hydrophobic-lytic properties resulting in trap-
ping at the site of administration, causing cell and tissue destruc-
tion leading to local and systemic adverse reactions.11 Wang and 
colleagues used different QS fractions to show cancer cell-killing 
effects,7 but they are too toxic to proceed to clinical testing. Thus, 
these free nonparticulate forms of QS demonstrate a low thera-
peutic index disqualifying them as candidate anticancer drugs. 
However, QS saponins formulated into 40 nm particles together 
with cholesterol and lipids have shown significantly reduced 
toxic effect on cells.11 A similar particle, an immune-stimulating 
complex (ISCOM), is currently used as an adjuvant and delivery 
system commercialized by Isconova AB (Uppsala, Sweden) 
for animal vaccines and is also in human phase III studies.11 
The ASAP and DSAP have been formulated into particles 
similar to the ISCOMs. The chemical stability of ISCOM is of 
significant practical value and has a shelf-life of several years 
in aqueous solutions at +2 °C to +8 °C (compared to months 
for free saponins). The particles are also intact and stable both 
in vitro and in vivo. No release of the integrated components 
of the particles are observed (Dr Karin Lövgren-Bengtsson, 
Isconova AB).11 In view of the well-known adjuvant effects of 
the two particles including stimulation and differentiation of 
immature and resting dendritic cells (manuscript in preparation), 
we decided to explore if the differentiation concept could be 
applied on cancer cell therapy.
In this study, we have elucidated the anticancer effects 
of the ASAP and DSAP particles. These particles were 
formulated using a similar technology as we applied for the 
formulation of ISCOMs.12 Because of their different modes of 
anticancer cell effects, ASAP particles were denoted killing 
and growth-inhibiting (KGI) and DSAP particles were denoted 
blocking and balancing effect (BBE). The results demonstrate 
that ASAP formulated into KGI particles, selectively kills 
tumor cells by apoptosis at a 30-fold lower concentration than 
that required to kill normal cells, indicating their potential as 
anticancer drugs. In contrast, nonparticulate ASAP kills both 
normal and cancer cells by lytic and necrotic effects.
Materials and methods
Acyl- and desacyl-saponins and their 
particulate formulations
Purified QS fractions, the acyl-saponin (ASAP) and its 
particulate form KGI and the desacyl-saponin (DSAP) and 
its particulate form BBE (Figures 1a and 1b), were kindly 
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Figure 1 selected Quillaja saponin (Qs) fractions, and their particulate forms. A) Reversed phase chromatography profile of QS. Fraction A (desacyl-saponin, DSAP) is the 
least hydrophobic Qs fraction being the active saponin component in BBe particles. Fraction B (acyl-saponin,   AsAP) is the most hydrophobic Qs fraction being the active 
component in KgI particles. B) The triterpenoid structure of Qs.   The core is a triterpenoid with two carbohydrate chains in the position 3 and 18 and an acyl chain terminated 
with arabinose and rhamnose monosaccharides demarked with a ring in the Figure. C) electron microscopic picture of KgI. BBe shows the same morphology.   The diameter 
of the spheres is about 40 nm.International Journal of Nanomedicine 2010:5 53
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supplied by Dr Karin Lövgren-Bengtsson (Isconova AB). 
These fractions are well characterized and used in com-
mercial and experimental vaccine adjuvant formulations.11,13 
The KGI and BBE particles were prepared as described 
previously.13 Briefly, to 0.05 mL of lipid mixture containing 
10 mg/mL each of cholesterol (C) and phosphatidylcholine 
(PC), 0.025 mL of ASAP/DSAP solution (100 mg/mL) and 
0.05 mL of phosphate-buffered saline (PBS) was added, 
mixed well and incubated at room temperature overnight. 
Then the mixture was dialyzed against PBS at room tem-
perature for three days with changing PBS every 12 hours. 
The particles were purified through a 10% sucrose cushion 
overnight at 50.000 rpm 10 °C in a SW50.1 rotor followed 
by re-suspension in PBS overnight.
electron microscopy
Samples of KGI and BBE particles were dialyzed against 
PBS, applied to formvar-coated copper grids and contrasted 
with 2% ammonium molybdate, pH 7.0. Photographs of the 
specimens were taken in Phillips 300 electron microscope 
at 60 kV accelerating voltage.14
cells
The human monoblast cell lines THP-1, acute lymphoblastic 
leukemia Jurkat, and human histiocytic lymphoma cell lines 
U937 and U937-Vcr were kindly provided by Prof. Kenneth 
Nilsson (Rudbeck laboratory, Uppsala University, Uppsala, 
Sweden). The myeloma RPMI 8226/S cell line and its 
sublines 8226/Dox40 and 8226/LR-5 were kind gifts from 
Dr William Dalton (Department of Medicine, Arizona Cancer 
Center, University of Arizona, Tucson, AZ). The human 
acute myelocytic leukemia cell line MV-4-11 was obtained 
from American Type Culture Collection (Rockville, MD). 
The acute lymphoblastic leukemia cell lines CCRF-CEM 
and its subline CEM/VM-1 were kind gifts from William 
Beck (Department of Pharmacology, College of Medicine, 
University of Tennessee, Memphis, TN).
8226/Dox40 was selected for doxorubicin resistance and 
shows the classical multidrug resistance (MDR) phenotype 
with overexpression of P-glycoprotein 170.15 8226/LR-5 was 
selected for melphalan resistance, proposed to be associated 
with increased levels of glutathione (GSH).16 U937-Vcr was 
selected for vincristine resistance, proposed to be tubulin-
associated.17 CEM/VM-1, selected for teniposide resistance, 
expresses an atypical MDR, which is proposed to be topoi-
somerase II (topoII)-associated.18
The cells were cultured in the recommended cell medium 
for the different cell lines. Normal human dendritic cells (DCs) 
and neutrophils were purchased from 3H Biomedical 
(Uppsala, Sweden).
For most experiments cell lines were grown in culture 
medium containing 10% fetal calf serum (FCS) under a humidi-
fied atmosphere with 5% CO2 at 37 °C in 96-well flat-bottomed 
micro-titer plates (Nunc, Roskilde, Denmark). For synchroniza-
tion, cells were starved for 22 hours by lowering of the serum 
concentration in the cell culture medium to 0.5%. The medium 
was then changed to medium containing 10% FCS.
Hemolytic activity
Hemolytic activity was assessed in chicken red blood cells 
(RBC) as described by Rönnberg and colleagues.10 The RBCs 
were washed with PBS and diluted to 0.5% in PBS. To 100 µl 
of this suspension, 100 µl of sample solution in PBS was 
added. The mixture was incubated at 37 °C for one hour and 
then centrifuged. Damaged cell membranes allow hemoglo-
bin to leak out into the supernatant. The absorbance of the 
supernatant was then measured at 414 nm in a Labsystems 
Multiskan MCC/340 microtitre plate reader.
cell viability
Trypan Blue (0.02%; National Veterinary Institute, Uppsala, 
Sweden) was used to analyze cell viability in nucleated cells. 
After exposure to saponin formulations, cells were stained 
with Trypan Blue. Stained dead and nonstained viable cells 
were counted in a microscope and the proportion of dead and 
live cells was calculated.
In some experiments the fluorometric microculture 
cytotoxicity assay (FMCA) was used for measurements of 
cell viability and cytotoxicity. Tumor cells were seeded in the 
presence or absence of the drug in 96-well micro-titer plates at 
a cell density of 5,000–20,000 cells/well. The FMCA is based 
on measurement of fluorescence generated from hydrolysis 
of fluorescein diacetate (FDA) to fluorescein by cells with 
intact plasma membranes and has been described in detail 
previously.19 The plates were incubated at 37 °C in humidified 
atmosphere containing 5% CO2 for 72 hours. At the end of 
the incubation period the medium was removed by aspira-
tion. After one wash in PBS, 50 µl/well of FDA dissolved in 
a physiological buffer (10 µg/mL) was added. The plates were 
incubated for 45 minutes and the generated fluorescence from 
each well was measured in a 96-well scanning fluorometer. 
The fluorescence is proportional to the number of intact cells 
in the well. Quality criteria for a successful analysis included 
a fluorescence signal in the control wells of more than five 
times the mean blank value, a mean coefficient of variation 
(CV) in the control wells of less than 30%.International Journal of Nanomedicine 2010:5 54
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Figure 2 Free non-particulate AsAP causes early cell destruction but not the particulate form.  A) cell destruction measured by hemolytic effect. KgI and BBe are virtually 
non-lytic while free   AsAP is highly lytic. B) Free   AsAP induces early cell death in human normal monocytes like in cancer cells, but not the   AsAP formulated into KgI particles 
measured by   Trypan Blue staining. C) Free   AsAP induces early cell death in U937 tumor cells within minutes at the concentrations indicated. KgI does not induce this rapid 
cell death. D) cell membrane destruction measured by the release of the intracellular enzyme thymidine kinase (TK) to the extracellular medium. Free   AsAP causes   TK 
release, while KgI does not cause the leakage. E) Free  AsAP causes cell necrosis but not KgI particles.
Apoptosis and necrosis
Apoptosis was analyzed by fluorescent-activated cell sorting 
(FACS). Briefly, 100 µl cell suspension (∼0.1–1 × 106 cells/mL) 
was transferred to a 5 mL culture tube. According essentially 
to the manufacturer’s instruction, after addition of 5 µl prop-
idium iodide (PI; 50 µg/mL) and 2.5 µl annexin V-FITC 
(200 µg/mL) (BD Biosciences, Stockholm, Sweden) the 
samples were incubated for 15 minutes in the dark at room 
temperature. Then 400 µl of 1 × binding buffer was added to 
each tube and the samples were analyzed within one hour.
A multiparametric single-cell assay was also used for 
measurement of apoptosis.20 Briefly, cells were plated in 
96-well plates with flat optical bottom (Perkin-Elmer Inc., 
Wellesley, MA), and incubated overnight before addition 
of drugs. At indicated time points, fluorescent probes were 
added to stain apoptotic markers: FAM-DEVD-FMK to stain 
activated caspase-3, MitoTracker Red to evaluate mitochon-
drial membrane potential (MMP) and Hoechst 33342 to stain 
the nucleus. Analysis was performed in the ArrayScan® high 
content screening system (Cellomics Inc, Pittsburgh, PA) 
which is a computerized automated fluorescence imaging 
microscope that automatically identifies stained cells and 
reports the intensity and distribution of fluorescence in 
individual cells. Automatic focusing, image acquisition and 
analysis were performed to collect data on a user-defined 
number of cells. Images and data regarding intensity and tex-
ture of the fluorescence within the individual cells, as well as 
the average fluorescence of the cell population within a well 
were stored in a database for easy retrieval and analysis.
Measurement of cell metabolic activity
The Alamar Blue assay was used essentially according rec-
ommendations from the supplier (Serotec Ltd, Oxford, UK). 
Briefly, the cells were adjusted to 2 × 105 cells/mL in RPMI 
1640 medium containing 10% FCS and 100 µg/mL kanamycin 
and 2 mM l-glutamine (GibcoBRL, Life Technologies AB, 
Täby, Sweden) and 100 µl/well cells cultured in 96-well 
plates (Nunc, Roskilde, Denmark). Then 100 µl/well of International Journal of Nanomedicine 2010:5 56
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various QS formulations or medium alone (as control) was 
added in triplicates. Alamar Blue was added to a final con-
centration of 10% to the wells after specified time points. The 
cell metabolic activity was subsequently measured for up to 
eight hours. The OD values were read at 570 and 600 nm in 
a spectrophotometer (Labsystems Multiskan RC, type 351). 
Metabolic activity is expressed as percent of the cell control 
(survival index; SI) and IC50 is defined as the concentrations 
of the QS formulations resulting in 50% metabolic inhibition 
compared to control.
Thymidine kinase (TK) activity
The TK activity was determined with a kit obtained from 
Biovica (Uppsala, Sweden). Briefly 100 µl cell suspension 
at a concentration of 0.1–1 × 106 cells/mL was transferred to 
Eppendorf tubes and centrifuged at 200 g for 10 minutes. The 
cell pellet was re-suspended in 100 µl cold PBS and freeze/
thawed 2–3 times. After centrifugation at maximum speed 
for five minutes, the supernatant was collected. Ten µl of the 
samples were used according to the manufacturer’s protocol. 
The extracellular, ie, released TK activity was measured as 
above directly on the cell culture medium.
cell cycle analysis
To investigate the effect of 0.25 and 1.00 µg/mL KGI and the 
effect of 10 and 100 µg/mL BBE on the cell cycle progres-
sion of tumor cells the lymphoma cell line, U937-GTB, was 
used. The U937-GTB cells were seeded in 12-well plates at 
1 × 106 cells/mL and exposed to the different concentrations 
of KGI and BBE for six and 24 hours. At the end of the 
exposure time, cells were collected, rinsed twice with PBS 
and fixed in 70% ice-cold ethanol. The cells were stored at 
a concentration of 2 × 105 cells/mL at -20 °C until analysis. 
The fixed cells were then centrifuged, the cell pellet was 
rinsed with PBS and suspended after centrifugation in 1 mL 
of 0.02 mg/mL PI staining solution with 0.2 mg/mL DNase-
free RNase and kept for 2 hours. DNA staining was then 
detected using the LSR II flow cytometer. ModFit LT software 
was used to analyze the percentage of the cells in different 
cell cycle phases.
Interleukin-8 production
Interleukin-8 (IL-8) was used for measurement of cellular 
cytokine production as a marker of tumor cell differentia-
tion after exposure to QS formulations. IL-8 was measured 
using a commercial ELISA kit from Endogen (Pierce 
Endogen, Rockford, IL, USA) according to the manufacturer’s 
instruction.
Results
chemical and physical structures 
of particulate KgI and BBe
Figure 1a illustrates QS separated by reversed phase chro-
matography as described previously.8,9 ASAP (see Figure 1a, 
fraction B) is highly hydrophobic owing to its acyl-chain 
(Figure 1b) and is the active component in the KGI 
particle distinguishing it from the BBE particle. The DSAP 
fraction A (Figure 1a, fraction A) lacking an acyl-chain has 
low hydrophobicity (Figure 1b) and is the active component 
in the BBE particle. KGI and BBE particles have equal 
morphology forming highly stable spherical particles with 
an average diameter of about 40 nm (Figure 1c).
Lytic and cytotoxic effects by free 
and nanoparticulate forms of AsAP 
and DsAP
The cell membrane lytic effect of the ASAP and DSAP or 
their particulate forms the KGI and BBE was measured on 
RBCs. Free ASAP lysed RBCs at a concentration of 5 µg/mL 
(Figure 2a) whereas the KGI particles induced RBC lysis at a 
20-fold higher concentration, ie, 100 µg/mL. Free DSAP did 
not cause lytic effects at concentrations up to 50 µg/mL as 
previously observed.10 The BBE particle did not lyse RBCs 
even at 100 µg/mL (Figure 2a).
The cell membrane lytic effect of the free ASAP or the 
particulate form of the ASAP (KGI) was then measured 
in normal human monocytes (see Materials and methods) 
(Figure 2b) and in the monoblast U937 tumor cells (Figure 2c) 
after Trypan Blue staining. At 50 µg/mL, free ASAP induced 
cell death in both the normal monocytes and the U937 tumor 
cells within 30 minutes. At 25 µg/mL, free ASAP killed all 
the normal monocytes within 30 minutes compared to three 
hours for U937 tumor cells. Also 10 µg/mL of free ASAP 
killed a proportion of the normal monocytes after two to 
three hours. In contrast, the KGI particles did not induce cell 
death in the normal monocytes at any concentration tested 
during the first three hours but cell death was only apparent 
after 18–24 hours. KGI at all concentrations was more active 
against tumor cells compared to normal cells at 18 hours 
(Figures 2b and 2c).
Rapid leakage of the enzyme TK into the medium was 
observed from cells exposed to free ASAP, but not with 
KGI, corroborated the hemolytic activity results (Figure 2d). 
Necrotic changes, measured using PI staining, were noted 
within six and 12 hours in cells exposed to 25 µg/mL free 
ASAP (Figure 2e). The results indicate that the saponin in International Journal of Nanomedicine 2010:5 57
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Figure 3 KgI kills preferentially cancer cells over normal cells with no recovery of residual cells while BBe blocks the killing effect of KgI. A) KgI induces cell death in U937 
monoblast cancer cells at about 30-fold lower concentration than that required to kill normal monocytes derived immature Dcs (mDc) measured by Alamar Blue method 
and expressed as Ic50. B) The U937 cancer cells were synchronized in cell cycle and then cultured with 2 µg/mL of KGI for the first three days. The viable cells were counted 
at indicated time points. even after a prolonged culture for 12 days there was no residual cancer cells treated with KgI reverting to replication. C) U937 cells were exposed 
to a fixed concentration of KGI (77 µg/mL) and increasing concentrations of BBe (X axis).   As shown, close to 100% blocking by BBe was achieved when the ratio between 
BBe and KgI approaching 10 to 1.
nanoparticulate form does not cause lytic reactions, cell 
membrane damage, and subsequent necrotic cell death.
KgI particles selectively kill monoblast 
U937 lymphoma cells
We selected the U937 cells to investigate the effects of KGI 
and BBE particles because of our background knowledge 
of tumor and normal cells of similar origin, ie, monocyte-
derived immature dendritic cells (DCs). We compared the 
killing effects by KGI and BBE on cancer cells with that 
on the monocyte derived normal DCs. KGI killed U937 
cells at a 30-fold lower concentration than was required to 
kill the normal DCs (Figure 3a). The effect on U937 cells 
was not reversible since the removal of the drug after three 
days did not allow cells to recover during the 12 days of 
culture. KGI at 2 µg/mL for three days reduced the cell 
number to 50% and eventually killed almost all tumor cells 
after 12 days of culture (Figure 3b), even 0.5 µg/mL of KGI 
caused continues repression of cancer cell growth during 
the 12 days of culture (data not shown). BBE did not induce 
cell death either in U937 or in normal DCs (Table 2). 
When a fixed concentration of 77 µg/mL KGI was mixed 
with increased concentrations of BBE, the killing effect 
of KGI was blocked in a concentration dependent manner. 
At a BBE:KGI ratio of 10:1, close to 100% blocking was 
observed (Figure 3c).
KgI kills cancer cells by apoptosis
KGI dose-dependently induced apoptosis in U937 cells 
with a peak after 24 hours of exposure as judged by annexin V 
staining, Figure 4a depicts one representative of three experi-
ments showing the same profile. At 24 and 48 hours an 
increase in DNA fragmentation as well as caspase 3/7 
activity (Figures 4b and 4d) was observed in the pres-
ence of intact plasma membranes, which is a hallmark of 
apoptosis.International Journal of Nanomedicine 2010:5 58
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KgI and cell cycle
The effect of KGI on the cell cycle in U937 cells was analyzed 
by assessment of the TK-activity over time. The TK activity 
was correlated with the inhibition of cell-metabolism (recorded 
by the Alamar Blue assay), induction of cell death (measured 
by Trypan Blue exclusion staining) and also with apoptosis 
(detected by annexin V staining). In nonsynchronized cells, 
KGI at 2 µg/mL caused a marked reduction of TK activity after 
exposure of the tumor cells for 48–72 hours (Figure 5a). Reduc-
tion of the TK activity after exposure to 25 or 50 µg/mL of KGI 
was already evident at 24 hours. Figure 5b demonstrates that 
tumor cells synchronized in the cell cycle exposed to 2 µg/mL 
of KGI for 24 hours had reduced intracellular levels of  TK 
compared to control cells coinciding with reduced number of 
viable cells (Figure 5c) indicating that the KGI-treated cells 
did not enter a second cycle. Corroborating these results, cell 
cycle analysis with flow cytometry of KGI-exposed DNA-
stained cells demonstrated accumulation of cells in G1 phase 
in parallel with depletion of cells in S-phase (Table 1).
KgI and BBe trigger differentiation 
of U937 cells
The capacity of KGI and BBE to induce U937 cells to produce 
interleukin-8 (IL-8), as a marker for differentiation, was tested. 
The production of IL-8 was around 600 pg/mL at the IC50 for 
KGI (Figure 5d). BBE did not kill the cells at concentrations 
tested and at the same concentration as the IC50 for KGI, 
around 400 pg/mL of IL-8 was produced (Figure 5d). For KGI 
the effect on IL-8 production was paralleled by cytotoxicity 
whereas BBE was not cell toxic but induced cell differentiation 
ie, IL-8 production. KGI and BBE formulations could also acti-
vate immature human DCs to produce cytokines and to express 
the DC differentiation marker CD86 (data not shown).
stand alone and synergistic effects  
of KgI and BBe on leukemic cell lines
The cytotoxic effect of KGI and BBE was tested in several 
leukemia cell lines using the FMCA and Alamar Blue assays 
(Table 2). The results demonstrated that several other leukemic 
cell lines showed high sensitivity to KGI including the vincri-
stine resistant subline U937-Vcr, acute lymphocytic leukemia 
CEM cells and acute myelocytic leukemia Mv-411 and 
THP-1 cells. In contrast, acute lymphocytic leukemia Jurkat- 
and etoposide-resistant CEM/R cells as well as the myeloma 
8226 cell lines were less sensitive. None of the cell lines tested, 
apart from U937-Vcr, was sensitive to BBE. Moreover, as seen 
in Figure 6, KGI and BBE exert strong synergistic effects with 
docetaxel and fludarabine on U937 cells, respectively.
Discussion
Free nonparticulate saponins of various origin including QS 
fractions exert cytotoxic activity on cancer cells.7 However, QS 
interacts with cholesterol present in the cell membranes on 
both normal and cancer cells, thereby trapping the free non-
particulate saponin at the site of administration,10 causing 
membrane damage, cell lysis, and subsequent necrosis result-
ing in a low therapeutic index. Possibly the free saponin binds 
more efficiently to cancer cells containing more cholesterol 
than normal cell, but that is not enough to give adequate 
therapeutic index to be of any clinical value.21,22
By formulating ASAP and DSAP with cholesterol into 
KGI and BBE nanoparticles respectively, the cell lytic 
toxicity is abolished. To note, no release of free ASAP or 
DSAP from the particles is recorded and the mode of action 
is connected to the particulate form. In contrast the concept 
for most particles intended for cancer treatment, eg, various 
Table 1 KgI induces depletion of U937 cancer cells in the s-phase 
and accumulation in g1-phase of the cell cycle measured as propor-
tion (%) of the total cell population
Phase in the  
cell cycle
Control cells  Cells + KGI (1 µg/mL) 
g1-phase 41 57
s-phase 50 27
Apoptosis 0.2 20
Abbreviation: KgI, killing and growth-inhibiting.
Table 2 cytotoxic effect of KgI and BBe on different leukemia 
cell lines and normal cells measured after exposure for 24 hours 
expressed as Ic50 (µg/mL)
Cell type Cell name KGI BBE
Tumor cells U937 0.33 100
U937/Vcr 0.3 9.4
ceM/s 0.54 100
ceM/R 6 100
THP-1 0.87 100
MV4-11 0.45 100
Jurkat 10 NDa
82226/s 11.5 100
8226/dox40 100 100
822/LR5 12.3 100
Normal cells Dc 24.32 1920b
  Neutrophils 50c ND
Notes: aNot done; bThe highest concentration used; cMeasured after five hours.
Abbreviations: BBe, blocking and balancing effect; Ic50, inhibitory concentration at 
half maximum; KGI, killing and growth-inhibiting; ND, not defined.International Journal of Nanomedicine 2010:5 59
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Figure 4 KgI particles induce apoptosis in U937 cells demonstrated in various assays. A) Induction of apoptosis by free AsAP and KgI particles measured by Annexin V 
staining. B) Photomicrograph of control and KgI treated cells stained with apoptag and Hoechst 33342. C) effect of KgI on DNA fragmentation. D) caspase 3/7 activity 
using   Arrayscan II as described in Material and Methods.
polymer particles including PLG particles is to gradually 
release the free active components.11,13
The cancer cell-killing effect of ASAP11,13 is related to 
toxicity manifested by hemolysis, cell membrane damage 
causing leakage of TK, decreased cell metabolism, and necro-
sis. The release of intracellular compounds by cell membrane 
damage including both normal and cancer cells causes even 
severe toxic effects in vivo.23 Thus, the therapeutic effect of 
free QA like ASAP is limited and out of the question for 
cancer treatment. Notably, free ASAP at 25 µg/mL induced 
a more rapid cell death of normal cells, ie, at 30 minutes vs 
one hour for U937 cells.
ASAP in the KGI particulate form caused U937 cancer 
cell death at low concentrations; 30-fold lower than what 
was required to kill the normal human monocytes or DCs, 
ie, a high therapeutic index was achieved. The high thera-
peutic index is explained by several factors. Firstly, fast 
replicating cancer cells are generally more sensitive than 
normal cells being the concept for cytostatic drugs. Secondly, 
by taking the cancer cells out of the cell cycle the essential 
recruitment/replacement of sensitive cancer cells is abol-
ished. Thirdly, by guiding the cancer cells to differentiation 
manifested by, eg, IL-8, leads eventually to programmed 
cell death. All together, those are factors that result in the 
evasion of side effects. The different modes of retarding the 
cancer cell growth by KGI and BBE from that of cytostatic 
drugs predispose for synergistic effects as demonstrated 
between docetaxel/KGI and fludarabine/BBE (Figure 6). 
KGI has in vivo studies shown high bioavailability after 
fast transport from the site of injection. In contrast the free 
form, being lytic, interacts with cell membranes causing 
local reactions and reduced bioavailability. KGI caused a 
late cell death by apoptosis requiring 12 hours or more to be 
observed. No reversal to cell replication was noticed during 
12 days of culture even when KGI was removed after three 
days. The lytic effect of ASAP on red blood cells and nucle-
ated cells was virtually abolished when formulated to KGI 
particles, and the cell death was confined to apoptosis. The 
apoptotic effect of KGI was preceded by exit from the cell 
cycle, G1 arrest (as shown in Table 1) followed by activation 
and differentiation observed as production of IL-8. KGI as 
well as BBE cause maturation effects on immature normal 
human dendritic cells with downregulation of CD14, produc-
tion of a number of pro-inflammatory cytokines, eg, IL-12, 
and expression of CD80, CD83, and CD86 (data not shown), 
which reinforces the concept that KGI and BBE stimulate International Journal of Nanomedicine 2010:5 60
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cancer cells to apoptosis like they do with normal cells by 
cell differentiation rather than a cytostatic effect.
Different methods were used to measure apoptosis 
(annexin V staining, apoptag, and Hoechst 33342 staining, 
DNA fragmentation and caspase 3/7 activation). All 
methods clearly demonstrate that KGI induces apoptosis. 
The annexin V staining reveals that KGI induces apoptosis 
and no necrosis is observed in the early phase. Over time the 
number of necrotic cells increases as shown with PI double 
staining with annexin V . The explanation is that apoptotic 
cells in vitro over time undergo necrosis while in vivo 
phagocytosed. Higher concentrations of KGI induced apop-
tosis earlier than lower concentrations. Apoptotic cells are 
prone to necrosis and become, therefore, stained by PI over 
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Figure 5 AsAP in free form and formulated into KgI inhibit thymidine kinase (TK) activity.   The decreased level of   TK caused by KgI correlates with reduced cell growth. Both 
KgI and BBe can induce cytokine production but only KgI kills the cells. A) Very low or no intracellular levels of   TK activity was recorded in U937 cancer cells treated with 
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time (double stained with both PI and annexin V), leading 
to reduction of the proportion of annexin V single positive 
cells (Figure 4a). In addition, the killing activity of KGI was 
not confined to U937 cells but was also observed on other 
leukemia cell lines as reflected in Table 2.
DSAP formulated into BBE particles had no cyto-
toxic effect on the U937 cells, but blocked the cancer cell 
killing effect of KGI in a concentration dependent manner, 
approaching complete blocking in a BBE: KGI ratio of 
10 to 1. This blocking indicates that BBE and KGI compete 
for one receptor and that KGI induced apoptosis probably 
requires a second receptor not targeted by DSAP and pos-
sibly related to the acyl-chain involving the terminal sugars 
arabinos and/or rhamnos. The indicated receptor activity 
has to be further elucidated in future studies.
KGI and BBE particles show high bioavailability and 
are virtually nontoxic, not causing local or systemic adverse 
effects in laboratory animals.11 A product similar to the KGI 
particle, ie, the ISCOM particle has been tested in more 
than 1000 humans as an adjuvant for vaccines and is in 
human phase III clinical trials for this indication.11 Thus, the 
combination of low toxicity, very high bioavailability, and 
high stability already observed in preclinical studies and in 
humans (Dr Karin Lövgren-Bengtsson, Isconova AB) indi-
cates a favorable therapeutic index and the possibility of a 
rapid advancement to clinical testing in cancer.
In addition to the potential use of nanoparticulate QS as 
stand alone anticancer drug, there are prospects for synergy 
between KGI and BBE as well as a number of registered 
cancer drugs eg, docetaxel and fludarabine (Figure 6). 
Besides direct pharmacodynamic interactions at the level of 
the tumor cell, the well documented adjuvant immunological 
effect of the QS particles11 might also augment the overall 
anticancer effect. Furthermore the KGI and BBE nanopar-
ticles should also be explored as potential carriers for estab-
lished anticancer drugs as they can be incorporated into the 
particles by various techniques24 as being successfully used 
commercially for delivery of vaccine antigens.11
There are other potential clinical applications of the 
particulate saponins. The nanoparticles may be targeted 
to the tumor cells by inserting tumor-targeting molecules, 
potentially increasing the selectivity of drug delivery, hence 
increasing the therapeutic index. This principle is illustrated 
by incorporating envelope proteins from respiratory viruses 
into particles, rendering enhanced delivery to the common 
mucosal immune system after intranasal mode of administra-
tion as described by Hu and colleagues.13,25 ISCOMs supplied 
with the DD portion of protein A of Staphylococcus aureus 
are targeting B cells.11 KGI supplied with the DD portion 
should target B cell lymphoma. The use of monoclonal anti-
bodies attached to the particles recognizing specific surface 
structures on tumor cells is a device for targeting.
In conclusion, QS saponin formulated into nanoparticles 
represents a potential new mechanistic category of anticancer 
drugs fundamentally different from standard cytotoxic drugs 
by being considerably more selective and also by stimulating 
differentiation. Furthermore, as drug carriers, the particles 
with inborn cancer cell-killing and immune-stimulating 
properties create interesting prospects for synergism with 
integrated standard anticancer compounds.
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